Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Name: Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
Published: 2016
License: Public Domain

GBG Forschungs GmbH · 2016

ClinicalTrials.gov · Datasets · License: Public Domain · 2016

Open Source ↗

breast-cancer pcr

breast cancer, triple negative breast neoplasms, hrpos breast neoplasms, brca 1 /2 and / or hrd, carboplatin, olaparib, pcr, neoadjuvant, triple-negative, hormonreceptor-positive, brca1/2, hrd, homologous recominant deficient

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 842302
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.